4172 Stock Overview
A specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InnoPharmax Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.10 |
| 52 Week High | NT$29.25 |
| 52 Week Low | NT$14.40 |
| Beta | 0.73 |
| 11 Month Change | 1.87% |
| 3 Month Change | -6.83% |
| 1 Year Change | -14.73% |
| 33 Year Change | 48.64% |
| 5 Year Change | 87.44% |
| Change since IPO | -46.94% |
Recent News & Updates
Shareholder Returns
| 4172 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | -14.7% | 7.5% | 30.3% |
Return vs Industry: 4172 underperformed the TW Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 4172 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 4172 volatility | |
|---|---|
| 4172 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4172 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4172's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 33 | Weihua Hao | www.innopharmax.com |
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases.
InnoPharmax Inc. Fundamentals Summary
| 4172 fundamental statistics | |
|---|---|
| Market cap | NT$1.82b |
| Earnings (TTM) | -NT$83.52m |
| Revenue (TTM) | NT$34.59m |
52.5x
P/S Ratio-21.7x
P/E RatioIs 4172 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4172 income statement (TTM) | |
|---|---|
| Revenue | NT$34.59m |
| Cost of Revenue | NT$15.06m |
| Gross Profit | NT$19.53m |
| Other Expenses | NT$103.04m |
| Earnings | -NT$83.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 56.46% |
| Net Profit Margin | -241.45% |
| Debt/Equity Ratio | 2.3% |
How did 4172 perform over the long term?
See historical performance and comparison